Do analysts recommend CALT or INDV?

Indivior has a consensus price target of $45.17, suggesting a potential upside of 26.06%. Given Indivior's stronger consensus rating and higher possible upside, analysts clearly believe Indivior is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Indivior 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00

Do analysts rate OGN or CALT?

Organon & Co. presently has a consensus target price of $11.40, suggesting a potential downside of 17.42%. Given Organon & Co.'s stronger consensus rating and higher possible upside, equities analysts clearly believe Organon & Co. is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organon & Co. 2 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.71 Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer RGC or CALT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, RGC or CALT?

Regencell Bioscience has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$11.70M N/A N/A Calliditas Therapeutics AB (publ) $1.60B 0.74 -$43.96M -$1.85 N/A

Calliditas Therapeutics AB (publ) (CALT) Competitors

$40.00 0.00 (0.00%)

As of 10/9/2026

Compare

CALT vs. INDV, OGN, RGC, TARS, and ARQT

Should you buy Calliditas Therapeutics AB (publ) stock or one of its competitors? Calliditas Therapeutics AB (publ)'s main competitors and comparable companies include Indivior (INDV), Organon & Co. (OGN), Regencell Bioscience (RGC), Tarsus Pharmaceuticals (TARS), and Arcutis Biotherapeutics (ARQT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Calliditas Therapeutics AB (publ) compare to Indivior?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Comparatively, 0.7% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Indivior has a consensus price target of $45.17, suggesting a potential upside of 26.06%. Given Indivior's stronger consensus rating and higher possible upside, analysts clearly believe Indivior is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Indivior has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Indivior	$1.24B	3.41	$210M	$2.79	12.84

In the previous week, Indivior had 4 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 4 mentions for Indivior and 0 mentions for Calliditas Therapeutics AB (publ). Indivior's average media sentiment score of 1.50 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Indivior is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Indivior	Very Positive

Indivior has a net margin of 26.65% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Calliditas Therapeutics AB (publ)'s return on equity of -212.04% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Indivior	26.65%	-283.11%	36.85%

Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, Indivior has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

Summary

Indivior beats Calliditas Therapeutics AB (publ) on 13 of the 17 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Organon & Co. has a net margin of 3.41% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Organon & Co.'s return on equity of 88.97% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.41%	88.97%	6.03%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Organon & Co. has higher revenue and earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.58	$187M	$0.77	17.93
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

Organon & Co. presently has a consensus target price of $11.40, suggesting a potential downside of 17.42%. Given Organon & Co.'s stronger consensus rating and higher possible upside, equities analysts clearly believe Organon & Co. is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Organon & Co. had 3 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 3 mentions for Organon & Co. and 0 mentions for Calliditas Therapeutics AB (publ). Organon & Co.'s average media sentiment score of 0.49 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Organon & Co. is being referred to more favorably in the media.

Company	Overall Sentiment
Organon & Co.	Neutral
Calliditas Therapeutics AB (publ)	Neutral

Organon & Co. has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 1.6% of Organon & Co. shares are held by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Organon & Co. beats Calliditas Therapeutics AB (publ) on 12 of the 15 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Regencell Bioscience had 3 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 3 mentions for Regencell Bioscience and 0 mentions for Calliditas Therapeutics AB (publ). Regencell Bioscience's average media sentiment score of 0.83 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Regencell Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Regencell Bioscience	Positive
Calliditas Therapeutics AB (publ)	Neutral

Regencell Bioscience has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ).

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$11.70M	N/A	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Regencell Bioscience has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Regencell Bioscience's return on equity of 0.00% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Regencell Bioscience has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

Summary

Regencell Bioscience beats Calliditas Therapeutics AB (publ) on 7 of the 11 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Tarsus Pharmaceuticals has a net margin of -7.67% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Tarsus Pharmaceuticals' return on equity of -13.53% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Tarsus Pharmaceuticals presently has a consensus target price of $100.86, suggesting a potential upside of 37.86%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Tarsus Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.70
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are owned by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Tarsus Pharmaceuticals has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market.

In the previous week, Tarsus Pharmaceuticals had 7 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 7 mentions for Tarsus Pharmaceuticals and 0 mentions for Calliditas Therapeutics AB (publ). Tarsus Pharmaceuticals' average media sentiment score of 0.51 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Tarsus Pharmaceuticals	Positive
Calliditas Therapeutics AB (publ)	Neutral

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	7.11	-$66.42M	-$1.09	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

Summary

Tarsus Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 13 of the 17 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Arcutis Biotherapeutics has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	8.88	-$16.14M	$0.21	126.57
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

In the previous week, Arcutis Biotherapeutics had 14 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 14 mentions for Arcutis Biotherapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Arcutis Biotherapeutics' average media sentiment score of 0.53 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Arcutis Biotherapeutics	Positive
Calliditas Therapeutics AB (publ)	Neutral

Arcutis Biotherapeutics presently has a consensus price target of $36.00, suggesting a potential upside of 35.44%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Arcutis Biotherapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.70
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Arcutis Biotherapeutics has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market.

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Arcutis Biotherapeutics has a net margin of 6.15% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Arcutis Biotherapeutics' return on equity of 15.05% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Summary

Arcutis Biotherapeutics beats Calliditas Therapeutics AB (publ) on 13 of the 16 factors compared between the two stocks.

Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CALT vs. The Competition

Export

Metric	Calliditas Therapeutics AB (publ)	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.19B	$12.38B	$7.26B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	22.58%
P/E Ratio	-21.62	800.12	275.65	25.82
Price / Sales	0.74	830.49	622.54	95.26
Price / Cash	N/A	15.28	27.30	36.12
Price / Book	37.74	9.01	10.85	6.10
Net Income	-$43.96M	$2.83B	$3.50B	$380.59M
7 Day Performance	N/A	-1.97%	-2.14%	-2.34%
1 Month Performance	N/A	-4.68%	-4.88%	-4.22%
1 Year Performance	N/A	-4.95%	6.00%	0.54%

Calliditas Therapeutics AB (publ) Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
INDV Indivior	4.6081 of 5 stars	$35.90 -0.3%	$45.17 +25.8%	+50.7%	$4.25B	$1.33B	12.87	838	Positive News
OGN Organon & Co.	1.0879 of 5 stars	$13.75 +0.3%	$11.40 -17.1%	+44.3%	$3.60B	$6.22B	17.85	10,000
RGC Regencell Bioscience	0.2672 of 5 stars	$7.35 +1.5%	N/A	-56.3%	$3.58B	N/A	N/A	10	News Coverage Earnings Report High Trading Volume
TARS Tarsus Pharmaceuticals	3.567 of 5 stars	$74.11 -0.5%	$100.86 +36.1%	+4.3%	$3.27B	$451.36M	N/A	370

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CALT) was last updated on 10/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Calliditas Therapeutics AB (publ) (CALT) Competitors

CALT vs. INDV, OGN, RGC, TARS, and ARQT

How does Calliditas Therapeutics AB (publ) compare to Indivior?

Summary

How does Calliditas Therapeutics AB (publ) compare to Organon & Co.?

Summary

How does Calliditas Therapeutics AB (publ) compare to Regencell Bioscience?

Summary

How does Calliditas Therapeutics AB (publ) compare to Tarsus Pharmaceuticals?

Summary

How does Calliditas Therapeutics AB (publ) compare to Arcutis Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALT vs. The Competition

Calliditas Therapeutics AB (publ) Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Calliditas Therapeutics AB (publ) (CALT) Competitors

CALT vs. INDV, OGN, RGC, TARS, and ARQT

How does Calliditas Therapeutics AB (publ) compare to Indivior?

Do insiders and institutionals hold more shares of CALT or INDV?

Do analysts recommend CALT or INDV?

Which has better valuation & earnings, CALT or INDV?

Does the media favor CALT or INDV?

Is CALT or INDV more profitable?

Which has more volatility and risk, CALT or INDV?

Summary

How does Calliditas Therapeutics AB (publ) compare to Organon & Co.?

Is OGN or CALT more profitable?

Which has stronger earnings & valuation, OGN or CALT?

Do analysts rate OGN or CALT?

Does the media favor OGN or CALT?

Which has more risk and volatility, OGN or CALT?

Do insiders & institutionals hold more shares of OGN or CALT?

Summary

How does Calliditas Therapeutics AB (publ) compare to Regencell Bioscience?

Do insiders and institutionals have more ownership in RGC or CALT?

Does the media refer more to RGC or CALT?

Which has preferable earnings and valuation, RGC or CALT?

Do analysts prefer RGC or CALT?

Is RGC or CALT more profitable?

Which has more risk and volatility, RGC or CALT?

Summary

How does Calliditas Therapeutics AB (publ) compare to Tarsus Pharmaceuticals?

Is TARS or CALT more profitable?

Do analysts recommend TARS or CALT?

Do institutionals & insiders hold more shares of TARS or CALT?

Which has more volatility & risk, TARS or CALT?

Does the media favor TARS or CALT?

Which has preferable earnings and valuation, TARS or CALT?

Summary

How does Calliditas Therapeutics AB (publ) compare to Arcutis Biotherapeutics?

Which has preferable valuation & earnings, ARQT or CALT?

Does the media favor ARQT or CALT?

Do analysts prefer ARQT or CALT?

Which has more volatility & risk, ARQT or CALT?

Do institutionals and insiders hold more shares of ARQT or CALT?

Is ARQT or CALT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALT vs. The Competition

Calliditas Therapeutics AB (publ) Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools